表紙
市場調查報告書

大麻二酚 (CBD) 治療藥:機會的評估、市場動態、開發平台分析

Cannabidiol (CBD) Drugs: Pipeline Analysis and Opportunity Assessment, H2 2018

出版商 GervanoRA Data Services LLP 商品編碼 769586
出版日期 內容資訊 英文 200 Pages
訂單完成後即時交付
價格
大麻二酚 (CBD) 治療藥:機會的評估、市場動態、開發平台分析 Cannabidiol (CBD) Drugs: Pipeline Analysis and Opportunity Assessment, H2 2018
出版日期: 2019年01月26日內容資訊: 英文 200 Pages
簡介

本報告提供全球大麻二酚 (CBD) 治療藥市場相關調查,市場概要,市場動態,開發平台治療藥的認證計劃預測,現在、未來的競爭情形,主要企業的簡介,新興企業的簡介,開發平台治療藥的說明與開發里程碑等相關分析。

第1章 簡介

第2章 摘要整理

第3章 大麻素治療藥概要

  • 大麻的展望
  • 全球大麻產品概要

第4章 市場動態

  • 政府的法規動態、影響
  • 契約
  • 新藥的認證 (EMA)
  • 新藥的認證 (USFDA)
  • 專利分析 (失效、學名藥)

第5章 開發平台分析、核准計劃的預測

  • 開發平台分析:各開發階段
  • 開發平台分析:各地區
  • 開發平台分析:各給藥途徑
  • 開發平台分析:各類藥物
  • 開發平台分析:各作用機制
  • 開發平台分析:各適應症
  • 開發平台分子分析:各原料 (植物來源 vs. 合成)
  • 開發平台分子分析:各類型 (大麻二酚 (CBD) vs. 四氫大麻酚 (THC))
  • 核准計劃的預測

第6章 大麻素的機會:各應用領域

  • 醫藥品產業
  • 食品產業
  • 化妝品產業

第7章 現在、未來的競爭情形

  • 企業
  • 大學、機關

第8章 簡稱

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GERPH223

GervanoRA's pipeline analysis and opportunity assessment report "Cannabidiol (CBD) Drugs: Pipeline Analysis and Opportunity Assessment, H2 2018" analyzed and assessed Cannabidiol pipeline molecules for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Cannabidiol Drugs industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Molecules by Geography, Pipeline Molecules by Drug Class, Pipeline Molecules by Mechanism of Action and Pipeline Molecules by Stage of development.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:

  • Unmet needs and Opportunities
  • Epidemiology and Epidemiology forecast 2019 - 2025
  • Market Dynamics with Coverage of Deals (Mergers, Acquisitions, Partnering, Collaborations etc.)
  • Patent Analysis of Pipeline Molecules
  • Pipeline Analysis and Estimated Pipeline Drug Approval Time lines
  • Clinical Trials Summary
  • Current and Future Competitive Landscape
  • Key Company Profiles with SWOT Analysis
  • Emerging Company Profiles with Opportunity Assessments
  • Pipeline Drug Descriptions along with Development milestones (Past and Future)
  • University Pipeline Molecules & In-Licensing/Out Licensing Opportunities

Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. REPORT DESCRIPTION
  • 1.2. METHODOLOGY
  • 1.3. UPCOMING AND OTHER AVAILABLE PIPELINE ANALYSIS REPORTS
  • 1.4. ABOUT US: GERVANORA DATA SERVICES

2. EXECUTIVE SUMMARY

  • 2.1. REPORT SUMMARY
  • 2.2. KEY EVENTS IN CANNABINOIDS COMPETITIVE SPACE
  • 2.3. KEY MAJOR FINDINGS
    • 2.3.1. DRIVERS
    • 2.3.2. RESTRAINTS
    • 2.3.3. UNMET NEEDS AND OPPORTUNITIES

3. CANNABINOIDS DRUGS OVERVIEW

  • 3.1. CANNABIS OUTLOOK
  • 3.2. GLOBAL CANNABIS PRODUCT OUTLINE

4. MARKET DYNAMICS

  • 4.1. GOVERNMENT REGULATORY DYNAMICS AND IMPACT
  • 4.2. DEALS (MERGERS/ ACQUISITIONS / COLLABORATIONS)
    • 4.2.1. ACQUISITIONS
    • 4.2.2. COLLABORATION AGREEMENTS
    • 4.2.3. LICENSING AGREEMENTS
    • 4.2.4. TERMINATION AGREEMENTS AND SETTLEMENTS
    • 4.2.5. PARTNERSHIPS
    • 4.2.6. AGREEMENTS
  • 4.3. NEW DRUG APPROVALS (EMA)
  • 4.4. NEW DRUG APPROVALS (USFDA)
  • 4.5. PATENT ANALYSIS (EXPIRES AND GENERICIZATION)

5. PIPELINE ANALYSIS AND ESTIMATED APPROVAL TIMELINE

  • 5.1. PIPELINE ANALYSIS BY STAGE OF DEVELOPMENT
    • 5.1.1. PRE-REGISTRATION (FILED) MOLECULES
    • 5.1.2. PHASE 3 MOLECULES
    • 5.1.3. PHASE 2 MOLECULES
    • 5.1.4. PHASE 1 MOLECULES
    • 5.1.5. PRECLINICAL MOLECULES
    • 5.1.6. EARLY R&D MOLECULES
    • 5.1.7. HSD-UNKNOWN
  • 5.2. PIPELINE ANALYSIS BY GEOGRAPHY
    • 5.2.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.3. PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION
    • 5.3.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.4. PIPELINE ANALYSIS BY DRUG CLASS
    • 5.4.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.5. PIPELINE ANALYSIS BY MECHANISM OF ACTION
  • 5.6. PIPELINE ANALYSIS BY INDICATION
    • 5.6.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.7. ANALYTICS ON PIPELINE MOLECULES BY SOURCE OF ORIGIN (PLANT DERIVED VERSUS SYNTHETIC ANALYTICS)
  • 5.8. ANALYTICS ON PIPELINE MOLECULES BY TYPE (CANNABIDIOL - CBD VS TETRAHYDROCANNABINOL -THC)
  • 5.9. ESTIMATED APPROVAL TIMELINES
    • 5.9.1. METHODOLOGY
    • 5.9.2. ESTIMATED APPROVAL TIMELINES US & EX-US

6. CANNABINOIDS OPPORTUNITIES BY AREA OF APPLICATION

  • 6.1. PHARMACEUTICAL INDUSTRY
    • 6.1.1. UNMET NEEDS AND OPPORTUNITIES
    • 6.1.2. EXPECTED MARKET IN 11MM
  • 6.2. FOOD INDUSTRY
    • 6.2.1. UNMET NEEDS AND OPPORTUNITIES
    • 6.2.2. EXPECTED MARKET IN 11MM
  • 6.3. COSMETIC INDUSTRY
    • 6.3.1. UNMET NEEDS AND OPPORTUNITIES
    • 6.3.2. EXPECTED MARKET IN 11MM

7. CURRENT AND FUTURE COMPETITIVE LANDSCAPE

  • 7.1. COMPANIES
    • 7.1.1. ESTABLISHED COMPANY PROFILES WITH SWOT ANALYSIS
      • 7.1.1.1. GW RESEARCH LTD
      • 7.1.1.2. ABBVIE INC
      • 7.1.1.3. INSYS THERAPEUTICS
      • 7.1.1.4. MYLAN PHARMA
      • 7.1.1.5. TILRAY
      • 7.1.1.6. CANOPY GROWTH
      • 7.1.1.7. AURORA CANNABIS
      • 7.1.1.8. GREEN THUMB INDUSTRIES
      • 7.1.1.9. CRONOS GROUP
    • 7.1.2. EMERGING COMPANIES WITH COMPETITIVE OPPORTUNITIES
      • 7.1.2.1. KALYTERA THERAPEUTICS
      • 7.1.2.2. BOTANIX PHARMACEUTICALS
      • 7.1.2.3. PHYTECS
      • 7.1.2.4. CV SCIENCES, INC
      • 7.1.2.5. SERINA THERAPEUTICS, INC
      • 7.1.2.6. INTEC PHARMA LTD
      • 7.1.2.7. AXIM BIOTECHNOLOGIES
      • 7.1.2.8. INMED PHARMACEUTICALS INC
      • 7.1.2.9. CARA THERAPEUTICS (COVERED CANNABINOID RELATED INFORMATION ONLY)
      • 7.1.2.10. VIVACELL BIOTECHNOLOGY ESPANA SL
      • 7.1.2.11. CARDIOL THERAPEUTICS INC
      • 7.1.2.12. PIVOT PHARMACEUTICALS
      • 7.1.2.13. ARTELO BIOSCIENCES
      • 7.1.2.14. TETRA BIO-PHARMA
      • 7.1.2.15. NEMUS BIOSCIENCE INC
      • 7.1.2.16. SCYTHIAN BIOSCIENCES
      • 7.1.2.17. ICD PHARMA
      • 7.1.2.18. CANADIAN CANNABIS MEDICAL TECHNOLOGIES
      • 7.1.2.19. ZYNERBA PHARMACEUTICALS
      • 7.1.2.20. THERAPIX BIOSCIENCES
      • 7.1.2.21. REVIVE THERAPEUTICS
      • 7.1.2.22. PANAG PHARMA
      • 7.1.2.23. ZELDA THERAPEUTICS PTY LTD
  • 7.2. UNIVERSITIES AND INSTITUTES

8. ABBREVIATIONS

LIST OF TABLES

  • TABLE 1: ECS STIMULATION ON DIFFERENT PARTS OF THE BODY
  • TABLE 2: AMOUNT SPENT ON MARIJUANA REASERCH, 2014-2017, US, IN $M
  • TABLE 3: MAJOR COLLABORATIVE AGREEMENTS INVOLVING CANNABINOID
  • TABLE 4: MAJOR LICENSING AGREEMENTS INVOLVING CANNABINOID
  • TABLE 5: MAJOR PARTNERSHIPS INVOLVING CANNABINOID
  • TABLE 6: MAJOR AGREEMENTS INVOLVING CANNABINOID
  • TABLE 7: EMA APPROVED CANNABIS DRUGS
  • TABLE 8: US FDA APPROVED CANNABIS DRUGS
  • TABLE 9: PHASE 3 MOLECULES IN THE CANNABINOID DRUG PIPELINE
  • TABLE 10: PHASE 2 MOLECULES IN THE CANNABINOID DRUG PIPELINE
  • TABLE 11: PHASE 1 MOLECULES IN THE CANNABINOID DRUG PIPELINE
  • TABLE 12: PRECLINICAL MOLECULES IN THE CANNABINOID DRUG PIPELINE
  • TABLE 13: EARLY R&D MOLECULES IN THE CANNABINOID DRUG PIPELINE
  • TABLE 14: HSD-UNKNOWN MOLECULES IN THE CANNABINOID DRUG PIPELINE
  • TABLE 15: CANNABINOID DRUG PIPELINE MOLECULES BY ORAL AS ROUTE OF ADMINISTRATION
  • TABLE 16: CANNABINOID DRUG PIPELINE MOLECULES BY TOPICAL AS ROUTE OF ADMINISTRATION
  • TABLE17: CANNABINOID DRUG PIPELINE MOLECULES BY INTRAVENOUS AS ROUTE OF ADMINISTRATION
  • TABLE 18: CANNABIDIOL DRUG PIPELINE MOLECULES BY TRANSDERMAL AS ROUTE OF ADMINISTRATION
  • TABLE 19: OTHER DIFFERENT ROUTE OF ADMINISTRATION FOR CANNABINOID DRUG PIPELINE
  • TABLE 20: CANNABINOID DRUG PIPELINE INDICATED FOR CANCER
  • TABLE 21: CANNABINOID DRUG PIPELINE INDICATED FOR CARDIOVASCULAR, METABOLICS & HEMATOLOGY
  • TABLE 22: CANNABINOIDDRUG PIPELINE INDICATED FOR CENTRAL NERVOUS SYSTEM
  • TABLE 23: CANNABINOID DRUG PIPELINE INDICATED FOR DERMATOLOGY
  • TABLE 24: CANNABINOID DRUG PIPELINE INDICATED FOR ENT & OPHTHALMOLOGY MARKET
  • TABLE 25: CANNABINOIDDRUG PIPELINE INDICATED FOR GASTROINTESTINAL MARKET
  • TABLE 26: CANNABINOID DRUG PIPELINE INDICATED FOR GENETIC AND RARE DISEASE MARKET
  • TABLE 27: CANNABINOID DRUG PIPELINE INDICATED FOR IMMUNOLOGY & INFLAMMATORY MARKET
  • TABLE 28: CANNABINOID DRUG PIPELINE INDICATED FOR INFECTIOUS DISEASE MARKET
  • TABLE 29: CANNABINOID DRUG PIPELINE INDICATED FOR RESPIRATORY MARKET
  • TABLE 30: CANNABINOID DRUG PIPELINE MOLECULES IN OTHER MARKET
  • TABLE 31: COMPANIES DEVELOPING PLANT DERIVED MOLECULES
  • TABLE 32: COMPANIES DEVELOPING SYNTHETIC MOLECULES
  • TABLE 33: COMPANIES DEVELOPING BIOSYNTHETIC MOLECULES
  • TABLE 34: COMPANIES DEVELOPING CBD MOLECULES
  • TABLE 35: COMPANIES DEVELOPING THC MOLECULES
  • TABLE 36: COMPANIES DEVELOPING CBD AND THC MOLECULES
  • TABLE 37: ESTIMATED APPROVAL TIMELINES OF PIPELINE MOLECULES
  • TABLE 38: GW RESEARCH PRODUCT PORTFOLIO
  • TABLE 39: R&D ACTIVITIES OF GW RESEARCH
  • TABLE 40: CONFERENCES/SEMINARS ATTENDED BY GW RESEARCH
  • TABLE 41: RECENT DEVELOPMENTS MADE BY GW RESEARCH
  • TABLE 42: SWOT ANALYSIS OF GW RESEARCH
  • TABLE 43: ABBVIE PRODUCT PORTFOLIO
  • TABLE 44: CONFERENCES/SEMINARS ATTENDED BY ABBVIE
  • TABLE 45: RECENT DEVELOPMENTS MADE BY ABBVIE
  • TABLE 46: SWOT ANALYSIS OF ABBVIE
  • TABLE 47: INSYS THERAPEUTICS PRODUCT PORTFOLIO
  • TABLE 48: R&D ACTIVITIES OF INSYS THERAPEUTICS
  • TABLE 49: CONFERENCES/SEMINARS ATTENDED BY INSYS THERAPEUTICS
  • TABLE 50: RECENT DEVELOPMENTS MADE BY INSYS THERAPEUTICS
  • TABLE 51: SWOT ANALYSIS OF INSYS THERAPEUTICS
  • TABLE 52: MYLAN PHARMA PRODUCT PORTFOLIO
  • TABLE 53: MYLAN PHARMA PRODUCT PIPELINE
  • TABLE 54: CONFERENCES/SEMINARS ATTENDED BY MYLAN PHARMA
  • TABLE 55: RECENT DEVELOPMENTS MADE BY MYLAN PHARMA
  • TABLE 56: SWOT ANALYSIS OF MYLAN PHARMA
  • TABLE 57: TILRAY PRODUCT PORTFOLIO
  • TABLE 58: CONFERENCES/SEMINARS ATTENDED BY TILRAY
  • TABLE 59: RECENT DEVELOPMENTS MADE BY TILRAY
  • TABLE 60: SWOT ANALYSIS OF TILRAY
  • TABLE 61: CANOPY GROWTH PRODUCT PORTFOLIO
  • TABLE 62: RECENT DEVELOPMENTS MADE BY CANOPY GROWTH
  • TABLE 63: SWOT ANALYSIS OF CANOPY GROWTH
  • TABLE 64: AURORA CANNABIS PRODUCT PORTFOLIO
  • TABLE 65: R&D ACTIVITIES OF AURORA CANNABIS
  • TABLE 66: RECENT DEVELOPMENTS MADE BY AURORA CANNABIS
  • TABLE 67: SWOT ANALYSIS OF AURORA CANNABIS
  • TABLE 68: GREEN THUMB INDUSTRIES PRODUCT PORTFOLIO
  • TABLE 69: CONFERENCES/SEMINARS ATTENDED BY GREEN THUMB INDUSTRIES
  • TABLE 70: RECENT DEVELOPMENTS MADE BY GREEN THUMB INDUSTRIES
  • TABLE 71: SWOT ANALYSIS OF GREEN THUMB INDUSTRIES
  • TABLE 72: CRONOS GROUP PRODUCT PORTFOLIO
  • TABLE 73: R&D ACTIVITIES OF CRONOS GROUP
  • TABLE 74: SWOT ANALYSIS OF CRONOS GROUP
  • TABLE 75: KALYTERA THERAPEUTICS FUTURE MILESTONES
  • TABLE 76: KALYTERA THERAPEUTICS RECENT DEVELOPMENTS AND MILESTONES
  • TABLE 77: BOTANIX PHARMACEUTICALS RECENT DEVELOPMENTS AND MILESTONES
  • TABLE 78: PHYTECS PRODUCT PORTFOLIO
  • TABLE 79: PHYTECS RECENT DEVELOPMENTS AND MILESTONES
  • TABLE 80: CV SCIENCES FUTURE MILESTONES
  • TABLE 81: CV SCIENCES RECENT DEVELOPMENTS AND MILESTONES
  • TABLE 82: SERINA THERAPEUTICSRECENT DEVELOPMENTS AND MILESTONES
  • TABLE 83: INTEC PHARMA FUTURE MILESTONES
  • TABLE 84: INTEC PHARMA RECENT DEVELOPMENTS AND MILESTONES
  • TABLE 85: AXIM BIOTECHNOLOGIES RECENT DEVELOPMENTS AND MILESTONES
  • TABLE 86: INMED PHARMACEUTICALS FUTURE MILESTONES
  • TABLE 87: INMED PHARMACEUTICALS RECENT DEVELOPMENTS AND MILESTONES
  • TABLE 88: VIVACELL BIOTECHNOLOGY RECENT DEVELOPMENTS AND MILESTONES
  • TABLE 89: CARDIOL THERAPEUTICS FUTURE MILESTONES
  • TABLE 90: CARDIOL THERAPEUTICS RECENT DEVELOPMENTS AND MILESTONES
  • TABLE 91: ARTELO BIOSCIENCES PRODUCT PORTFOLIO
  • TABLE 92: RECENT DEVELOPMENTS AND FUTURE MILESTONES OF ARTELO BIOSCIENCES
  • TABLE 93: TETRA BIO-PHARMA FUTURE MILESTONES
  • TABLE 94: TETRA BIO-PHARMA RECENT DEVELOPMENTS AND MILESTONES
  • TABLE 95: NEMUS BIOSCIENCE RECENT DEVELOPMENTS AND MILESTONES
  • TABLE 96: ZYNERBA PHARMACEUTICALS FUTURE MILESTONES
  • TABLE 97: ZYNERBA PHARMACEUTICALS RECENT DEVELOPMENTS AND MILESTONES
  • TABLE 98: ZELDA THERAPEUTICS FUTURE MILESTONES
  • TABLE 99: ZELDA THERAPEUTICS RECENT DEVELOPMENTS AND MILESTONES
  • TABLE 100: UNIVERSITIES AND INSTITUTES CONDUCTING RESEARCH ON CANNABINOIDS

LIST OF FIGURES

  • FIGURE 1: KEY PIPELINE EVENTS, 2019-2032
  • FIGURE 2: KEY PIPELINE EVENTS, 2019-2021
  • FIGURE 3: PHARMACODYNAMIC EFFECTS OF KEY CANNABINOIDS
  • FIGURE 4: OVERALL DEALS ACTIVITY INVOLVING CANNABINOID
  • FIGURE 5: GEOGRAPHY WISE BREAK UP V/S DEAL TYPE
  • FIGURE 6: CANNABINOID DRUG PIPELINE ANALYSIS BY STAGES OF DEVELOPMENT
  • FIGURE 7: CANNABINOID DRUG PIPELINE ANALYSIS BY GEOGRAPHY
  • FIGURE 8: CANNABINOID DRUG PIPELINE ANALYSIS BY STAGES OF DEVELOPMENT V/S GEOGRAPHIES
  • FIGURE 9: CANNABINOID DRUG PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION
  • FIGURE 10: CANNABINOID DRUG PIPELINE ANALYSIS BY INDICATION
  • FIGURE 11: GRAPHICAL VIEW OF PIPELINE MOLECULE'S STAGE OF DEVELOPMENT VS SOURCE OF ORIGIN
  • FIGURE 12: GRAPHICAL VIEW OF PIPELINE MOLECULE'S GEOGRAPHY VS SOURCE OF ORIGIN
  • FIGURE 13: PIPELINE MOLECULE'S ANALYTICS BY TYPE (CBD VS THC)
  • FIGURE 14: GRAPHICAL VIEW OF PIPELINE MOLECULE'S STAGE OF DEVELOPMENT VS MOLECULE TYPE
  • FIGURE 15: GRAPHICAL VIEW OF PIPELINE MOLECULE'S GEOGRAPHY VS MOLECULE TYPE
  • FIGURE 16: CANNABINOID OPPORTUNITY ASSESSMENT
  • FIGURE 17: TOTAL CANNABINOID MARKET, 2016 V/S 2025
  • FIGURE 18: PHARMACEUTICAL INDUSTRY CANNABINOID MARKET, 2016 V/S 2025
  • FIGURE 19: FOOD INDUSTRYCANNABINOID MARKET, 2016 V/S 2025
  • FIGURE 20: COSMETIC INDUSTRYCANNABINOID MARKET, 2016 V/S 2025
  • FIGURE 21: FINANCIAL INFORMATION OF GW RESEARCH
  • FIGURE 22: FINANCIAL INFORMATION OF ABBVIE
  • FIGURE 23: FINANCIAL INFORMATION OF INSYS THERAPEUTICS
  • FIGURE 24: FINANCIAL INFORMATION OF MYLAN PHARMA
  • FIGURE 25: FINANCIAL INFORMATION OF TILRAY
  • FIGURE 26: FINANCIAL INFORMATION OF CANOPY GROWTH
  • FIGURE 27: FINANCIAL INFORMATION OF AURORA CANNABIS
  • FIGURE 28: FINANCIAL INFORMATION OF GREEN THUMB INDUSTRIES
  • FIGURE 29: FINANCIAL INFORMATION OF CRONOS GROUP